FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer By Ogkologos - February 6, 2025 539 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the eXALT3 study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Addressing Common Concerns Around Taking Opioids for Cancer-Related Pain: An Expert... July 5, 2023 Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Improves EFS and OS in Cisplatin-Eligible... November 18, 2024 For Esophageal Cancer, Immunotherapy Likely to Play Larger Role October 19, 2020 Popular Fitness Instructor Encourages Others to Maintain Routine Check Ups After... February 9, 2021 Load more HOT NEWS EMA Recommends Extension of Indications for Alectinib to Adjuvant Treatment of... Daughter Surprises Terminally Ill Mom With Graduation Ceremony In Hospital Room. Adagrasib Shows Clinical Efficacy in Patients with Previously Treated KRASG12C-Mutated Advanced... Women in science: Cancer research pioneers – part 2
